GlobeNewswire Inc.··NaAssembly Biosciences Advances Pipeline With $226.6M Cash Runway Into 2028
Assembly Biosciences reports Q1 2026 results with $226.6M cash runway into 2028, completing Phase 1b herpes studies and advancing hepatitis delta candidate toward Phase 2.
GILDASMBclinical developmentGilead Sciences